Zomedica Corp. specializes in veterinary diagnostics and therapeutic devices targeting companion animals, leveraging patented Bulk Acoustic Wave technology and a growing product lineup including TRUFORMA and VETIGEL. Despite substantial investments in R&D and expanding its manufacturing footprint, the company has experienced widening net losses and negative operating cash flow over recent years. Its strategic mix of product innovation, acquisitions, and diversified sales channels offers upside potential; however, financial sustainability remains a core risk as Zomedica continues to navigate low gross margins and high operating expenses. Future revenue growth hinges on wider adoption of its diagnostic platforms and therapeutic devices, balanced against capital constraints and competitive dynamics in veterinary health.